1. Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1.
- Author
-
Huang, Wenpeng, Son, Mai Hong, Ha, Le Ngoc, Kang, Lei, and Cai, Weibo
- Subjects
PEPTIDES ,MACROCYCLIC compounds ,PROGRAMMED death-ligand 1 ,BRAF genes - Abstract
A recent article in the European Journal of Nuclear Medicine & Molecular Imaging discusses the development of a macrocyclic peptide PET radioligand for PD-L1, a protein involved in immune checkpoint mechanisms. The article highlights the challenges and opportunities in individualizing treatment for patients who could benefit from anti-PD-1/PD-L1 therapy and monitoring their response during therapy. The authors present a study on the discovery and evaluation of a novel fluorine-18 labeled macrocyclic peptide-based PET ligand, [18F]BMS-986229, which demonstrated high affinity for PD-L1 and rapid clearance from non-PD-L1 tissues. The study suggests that this ligand has the potential to facilitate a broader clinical application of PD-L1 PET imaging. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF